Product Image

Contributor Information

  • Name Luke Gaughan
  • Institute Newcastle University

Tool Details

  • Tool name: CWR22Rv1-AR-EK cell line
  • Alternate names: AR-V
  • Tool type: Cell Lines
  • Tool sub-type: Continuous
  • Parental cell line: CWR22Rv1
  • Organism: Human
  • Cancer type: Genitourinary cancer
  • Disease: Cancer
  • Model: Knock-In
  • Conditional: No
  • Description: Resistance to androgen receptor (AR)-targeted therapies in prostate cancer (PC) is a major clinical problem. A key mechanism of treatment resistance in advanced PC is the generation of alternatively spliced forms of the AR termed AR variants (AR-Vs) that are refractory to targeted agents and drive tumour progression. Our understanding of how AR-Vs function is limited due to difficulties in distinguishing their discriminate activities from full-length AR (FL-AR). The CWR22Rv1-AR-EK (Androgen Receptor-Exon Knockout) cell line is a prostate cancer cell line which is knockout for FL-AR (by CRISPR) but retains expression of all endogenous AR-Vs making it a valuable model for the study of receptor splice variants. This new derivative is dependent upon AR-Vs for growth and is refractory to all FL-AR-targeting agents. CRISPR edited CWR22Rv1 cells.
  • Research area: Cancer; Drug development
  • Production details: CRISPR-derived cell line that has lost expression of full length androgen receptor (FL-AR), but retains all endogenous androgen receptor variants (AR-Vs). Two gRNAs were designed to target distinct loci within exon 5 of the AR gene. To knock-in a stop codon into exon 5 of the AR locus, a 180 bp ssODN template was designed containing a central TAA sequence and flanked by 75 bp 5â?‚€?‹Â› and 3â?‚€?‹Â› termini 100% complementary to the AR gene sequence.
  • Additional notes: CRISPR edited CWR22Rv1 cells. Cancer Research Technology Limited (trading research tools as Ximbio) has been granted a non-exclusive license to the CRISPR-Cas9 technology by ERS Genomics Ltd under the patent rights listed here. This license from ERS Genomics Ltd allows Ximbio to develop and commercialise CRISPR-Cas9 modified cell lines for research use only. Ximbio can provide these modified CRISPR-Cas9 cell lines to companies under a label-use only license.

  • For Research Use Only

Target Details

  • Target: Androgen Receptor variants

Application Details

  • Application notes: Cancer Research Technology Limited (trading research tools as CancerTools.org) has been granted a non-exclusive license to the CRISPR-Cas9 technology by ERS Genomics Ltd under the patent rights listed here: https://www.cancertools.org/tool-faqs#hs_cos_wrapper_widget_1649861453796 This license from ERS Genomics Ltd allows CancerTools.org to develop and commercialise CRISPR-Cas9 modified cell lines for research use only. CancerTools.org can provide these modified CRISPR-Cas9 cell lines to companies under a label-use only license

Handling

  • Format: Frozen
  • Growth medium: RPMI 1640 media supplemented with 10% foetal calf serum (FCS) and 5% L-glutamine at 37?‚°C
  • Storage conditions: Liquid Nitrogen
  • Shipping conditions: Dry ice
  • Mycoplasma free: Yes
  • Biosafety level: 1

Documentation

Related Tools

Product Image

HM3 Cell Line

#153328
Product Image

HeLa FRT/TO (YFP-Astrin Delta70 siRNA res) cell line

#157865
Product Image

MSS-PT16 cell line

#161755

References

  • •  Kounatidou et al. 2019. Nucleic Acids Res. 47(11):5634-5647. PMID: 31006810.